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Purpose: During the past decades many treatments and devices
were developed in attempt to unload the diseased articular sur-
face in knee osteoarthritis (OA). A novel biomechanical device
and treatment methodology (The APOS System) was introduced
in order to unload the diseased articular surface during activ-
ity (dynamic wedging), strengthen dynamic stabilizers and train
neuromuscular control by means of controlled biomechanical
perturbations. The purpose of this study is to examine the ef-
fectiveness of APOS System in reducing pain and improving
function in knee OA patients.
Methods: A double blind, randomized, prospective study was
performed with 61 knee OA patients, aged 49-83 (66±8.1) years
and graded 1-4 (3±1) according to Kellgren & Lawrence. Patients
were randomized into research (active) and control (placebo)
groups. All patients underwent 8 weeks of treatment. Patients
were examined at baseline and supervised 4 times during the
study. Patients in the research group used the biomechanical
device that consists of 2 biomechanical elements located under
the strategic weight bearing spots of each of the patient’s feet
and a mounting and positioning mechanism embedded in desig-
nated shoes. The treatment methodology that was applied to the
research group included dynamic wedging of the diseased artic-
ular surface. Patients in the control group used a placebo device
without the biomechanical elements. Patients were assessed at
baseline, after 4 weeks and after 8 weeks at the end of the study
using Knee Society Score, WOMAC, SF-36, ALF and VAS. The
assessment was performed without the examiner knowing the
group affiliation of the patient.
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Results: The two groups were statistically similar (p>0.05) at
baseline with respect to age, Kellgren & Lawrence classification
and all assessed parameters including subscales. Significant dif-
ference between groups over time was observed for Knee Score
(p<0.001), Knee Society Function Score (p<0.001), WOMAC
(p<0.001), SF-36 (p<0.001), ALF (p<0.001) and VAS (p<0.001).
Significant improvement was observed in the research group
throughout all assessed parameters (measured improvement for
Knee Score, Knee Society Function Score, WOMAC, SF-36, ALF
and VAS were a multiplication of 1.8, 1.4, 3, 1.4, 1.35 and 2 in
the applicable scale respectively). A slight deterioration was ob-
served in the control group throughout all assessed parameters
at final assessment.
Conclusions: The findings demonstrate that APOS System is
effective and significantly improves function and reduces pain
among knee OA patients.
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Purpose: The Glucosamine/chondroitin Arthritis Intervention
Trial (GAIT) was a double-blind, placebo-controlled, random-
ized, clinical trial comparing glucosamine (G), chondroitin sulfate
(CS), the combination of G and CS, and celecoxib (CE) to
placebo (PL). A high (60.1%) placebo response rate was ob-
served. GAIT patients were not required to flare before study
entry in contrast to many other OA trials. This analysis com-
pares the pain improvement responses of patients who met flare
criteria at entry with those who did not.
Methods: GAIT patients were required to have clinical and
radiographic OA and a summed WOMAC Pain score of 125-400
mm. Patients had screening (V0) and randomization (V1) visits.
Patients had to undergo OA medication washout before V1. Flare
was defined as increases of (a) 15 mm in WOMAC walking pain
and (b) Likert Physician Global of Disease Severity ≥1 between
V0 and V1. Response was defined as 20% improvement in
summed WOMAC Pain between randomization and 6 months of
treatment, and by OMERACT/OARSI criteria (O/O).
Results: 1583 patients were recruited to the study and random-
ized into the five treatment arms. 22.9% met the flare criteria.
Demographics were similar among the treatment groups. The
mean age was 58.6 years, 64.1% were female, mean summed
WOMAC pain was 235.9 and 38.2% were Kellgren & Lawrence
Grade 3. Response rates are summarized in the tables below:
All randomized patients (N=1583)
G CS G+CS CE PL
20% Response 64% 65.4% 66.6% 70.1% 60.1%
Effect Size 0.08 0.10 0.13 0.21
O/O Response 60.6% 63.5% 65.6% 67.3% 56.9%
Effect Size 0.08 0.14 0.18 0.21
Patients meeting flare criteria (N=362)
G CS G+CS CE PL
20% Response 62.7% 68.8% 73.9% 74.6% 69.3%
Effect Size -0.14 -0.01 0.10 0.12
O/O Response 61.4% 68.8% 72.5% 70.4% 68.0%
Effect Size -0.14 0.02 0.10 0.05
Patients not meeting flare criteria (N=1221)
G CS G+CS CE PL
No Flare (N=1221)
20% Response 64.5% 64.6% 64.5% 68.8% 57.1%
Effect Size 0.15 0.15 0.15 0.24
O/O Response 60.3% 62.2% 63.7% 66.4% 53.4%
Effect Size 0.14 0.18 0.21 0.27
Conclusions: Differences between active treatments and
placebo are smaller in patients who flare because placebo re-
